Commerzbank Aktiengesellschaft’s Achillion Pharmaceuticals ACHN Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-50,102	Closed	-$207K	–	1014
2016 Q4	$207K	Buy	50,102 +699	+1%	+$3.72K	﹤0.01%	892
2016 Q3	$400K	Buy	49,403 +251	+0.5%	+$2.13K	0.01%	632
2016 Q2	$383	Sell	49,152 -1,334	-3%	-$11.4K	﹤0.01%	754
2016 Q1	$390K	Sell	50,486 -368	-0.7%	-$2.69K	﹤0.01%	770
2015 Q4	$549K	Buy	50,854 +1,484	+3%	+$13.5K	﹤0.01%	842
2015 Q3	$341K	Sell	49,370 -2,713	-5%	-$22.1K	﹤0.01%	916
2015 Q2	$461K	Sell	52,083 -30,962	-37%	-$293K	﹤0.01%	996
2015 Q1	$819K	Buy	+83,045	New	+$1.04M	﹤0.01%	844
2014 Q2	–	Sell	-10,355	Closed	-$34K	–	1253
2014 Q1	$34K	Buy	+10,355	New	+$36.2K	﹤0.01%	1184
2013 Q3	–	Sell	-28,519	Closed	-$233K	–	1461
2013 Q2	$233K	Buy	+28,519	New	+$218K	﹤0.01%	1331

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Commerzbank Aktiengesellschaft's ACHN Position: Q1 2017 in Review

Commerzbank Aktiengesellschaft sold out of Achillion Pharmaceuticals (ACHN) in Q1 2017, closing a stake of 50,102 shares — an estimated $207K sold.

Commerzbank Aktiengesellschaft first reported a position in ACHN in Q2 2013 and held it in 10 quarters. The position peaked at $819K in Q1 2015. 130 funds tracked by Wall St. Rank hold ACHN as of Q1 2017.

Commerzbank Aktiengesellschaft reported no remaining Achillion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Commerzbank Aktiengesellschaft sold 50,102 Achillion Pharmaceuticals shares in Q1 2017, an estimated $207K.
Commerzbank Aktiengesellschaft first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Commerzbank Aktiengesellschaft's Achillion Pharmaceuticals position peaked at $819K in Q1 2015.
130 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2017.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q1 2017, filed 1 May 2017.